R&D Trends

Lundbeck, IBM Watson Health collaborate on neurological disorders

Monday, January 30, 2017

Lundbeck is collaborating with IBM‘s Watson Health to accelerate the development of innovative medicines to treat psychiatric and neurological disorders. The collaboration will combine Lundbeck’s expertise in the treatment of psychiatric and neurological disorders with IBM’s cognitive and knowledge-based analytics to foster the discovery and development of new innovative treatments of disorders such as schizophrenia and Parkinson’s disease.

[Read More]

J&J to acquire Actelion for $30B, spin-out new R&D company

Friday, January 27, 2017

Johnson & Johnson and Actelion have entered into a definitive transaction agreement under which Johnson & Johnson will launch an all-cash tender offer in Switzerland to acquire all of the outstanding shares of Actelion for $280 per share, payable in U.S. dollars, which equates to CHF 280.08 per share as of January 25, 2017. The transaction, which was unanimously approved by the boards of directors of both companies, is expected to be immediately accretive to Johnson & Johnson adjusted earnings per share and accelerate Johnson & Johnson revenue and earnings growth rates. Johnson & Johnson will fund the transaction with cash held outside the U.S.

[Read More]

NIH initiates pilot grant program for innovative neurological research

Friday, January 27, 2017

The first 30 recipients of the new R35 Research Program Award (RPA), a pilot program designed to encourage creative research by enhancing funding stability, have been announced by the National Institute of Neurological Disorders and Stroke (NINDS), part of the NIH. NINDS-supported investigators who secure an RPA will have their research funded for a period of five years, with the potential to have that funding extended for up to an additional three years. This funding initiative was developed to provide support for a grantee’s overall research program, not just individual projects. 

[Read More]

Report: API market size worth $239.8B by 2025

Tuesday, January 24, 2017

The global active pharmaceutical ingredients (API) market is expected to reach a value of $239.8 billion by 2025, based on a new report by Grand View Research. The rising prevalence of lifestyle-induced & age-related diseases and cancer is projected to drive the market over the forecast period. Advancements in recombinant molecular technologies and high capitalization for development of novel drugs are also estimated to boost growth. 

[Read More]

Chan Zuckerberg Initiative to acquire AI startup Meta

Tuesday, January 24, 2017

iGan Partners is thrilled to announce the pending acquisition of its portfolio company, Meta, by the Chan Zuckerberg Initiative. Launched in 2015 by Mark Zuckerberg and Dr. Priscilla Chan, the Chan Zuckerberg Initiative is dedicated to advancing human potential and promoting equal opportunity, with a current focus on scientific research, education, and building strong communities. The goal of their science initiative is to cure, prevent, or manage all diseases by the end of this century.

[Read More]

Caris Life Sciences, Lustgarten Foundation collaborate

Monday, January 23, 2017

Caris Life Sciences, an innovator in molecular science, and the Lustgarten Foundation, a private funder of pancreatic cancer research, are collaborating to support a clinical trial evaluating the impact of immunotherapy in the treatment of pancreatic cancer. Caris is providing clinical trial enrollment services to identify potential trial candidates based on biomarker expression results and facilitate communication between treating physicians and study investigators. The Lustgarten Foundation is a sponsor of the study for pancreatic cancer patients in support of its mission to advance scientific and medical research related to the diagnosis, treatment and cure of pancreatic cancer. [Read More]

BASF, Nuritas partner on peptide ingredients through artificial intelligence

Monday, January 23, 2017

BASF Human Nutrition and Nuritas have announced a collaboration that will see the commercialization and discovery of health-benefiting bioactive peptide networks within specific target areas of significant value. Peptides are biologically occurring short chains of amino acids that act as potent signaling molecules in the body. The peptide networks of focus in this collaboration are natural, food-derived, patented and of significant benefit to the health of consumers. These health benefits include for example anti-inflammatory activities. 

[Read More]